返回Google圖書搜尋

A Novel Cas9 Fusion Protein Promotes Targeted Genome Editing with Reduced Mutational Burden in Primary Human Cells

Antonio CarusilloSibtain HaiderRaul SchäferManuel RhielDaniel TürkKay O. ChmielewskiJulia KlermundLaura MostiAndrieux GeoffroyRichard SchäferTatjana I. CornuAnton CathomenClaudio Mussolino

出版	Universität, 2023
URL	http://books.google.com.hk/books?id=CbMV0AEACAAJ&hl=&source=gbs_api

註釋Abstract: Precise genome editing requires the resolution of nuclease-induced DNA double strand breaks (DSBs) via the homology-directed repair (HDR) pathway. In mammals, this is typically outcompeted by non-homologous end-joining (NHEJ) that can generate potentially genotoxic insertion/deletion mutations at DSB sites. Because of higher efficacy, clinical genome editing has been restricted to imperfect but efficient NHEJ-based approaches. Hence, strategies that promote DSB resolution via HDR are essential to facilitate clinical transition of HDR-based editing strategies and increase safety. Here we describe a novel platform that consists of a Cas9 fused to DNA repair factors to synergistically inhibit NHEJ and favor HDR for precise repairing of Cas-induced DSBs. Compared to canonical CRISPR/Cas9, the increase in error-free editing ranges from 1.5-fold to 7-fold in multiple cell lines and in primary human cells. This novel CRISPR/Cas9 platform accepts clinically relevant repair templates, such as oligodeoxynucleotides (ODNs) and adeno-associated virus (AAV)-based vectors, and has a lower propensity to induce chromosomal translocations as compared to benchmark CRISPR/Cas9. The observed reduced mutational burden, resulting from diminished indel formation at on- and off-target sites, provides a remarkable gain in safety and advocates this novel CRISPR system as an attractive tool for therapeutic applications depending on precision genome editing